Episode 4: Two-Week Takedown. Is Librela dangerous (?) and a new weekly NSAID.

1.The GP hook

What’s new in the consult room this fortnight? A stronger anti‑itch tablet on the shelves, a storm around Librela, a once‑weekly NSAID that splits opinion, and a faecal calprotectin test you can run in‑house. Here’s how we’re approaching them in real GP practice.

What’s landed in the consult room these last two weeks? A new once‑daily JAK option for itchy dogs, renewed debate about Librela, a once‑weekly NSAID that’s stirring unease, and an in‑clinic faecal calprotectin lateral‑flow test. Below are the practical points we actually discussed on the pod, how we’re approaching them in GP practice, and short scripts you can steal for consults.

2.Quick snapshot

• Zenrelia — a once‑daily JAK inhibitor some clinics are trialling when Apoquel control slips.
• Librela — still helps many older dogs with OA; referral reports of rapidly progressive osteoarthritis have made us more cautious in younger/middle‑aged orthopaedic patients.
• Daxo Cox — being marketed as a once‑weekly, COX‑2‑selective NSAID; raises practical concerns around reversibility, anaesthesia and emergency steroid needs.
• GI Quest — an in‑clinic faecal calprotectin lateral‑flow test for dogs and cats to help identify intestinal inflammation at the point of care.

3.Zenrelia (new JAK option) — where it fits

What we heard on the floor and at LVS

How we’re using it in practice

Monitoring and pitfalls

Short owner script

“We can keep using Apoquel if it controls your dog, or try Zenrelia, which is once‑daily and may help some dogs who relapse when stepping down. If we switch we’ll agree a monitoring plan and review date.”

Clinical note

• Reps and some clinics report good results. The big selling points: once‑daily dosing from the outset (no twice‑daily “loading”) and, anecdotally, fewer step‑down relapses compared with Apoquel in some dogs.
• Pharmacology: Zenrelia targets a slightly different JAK profile (it includes JAK2 activity). That’s why trial authors and reps noted small falls in some haematology parameters in study populations; the study authors described those shifts as small and not clearly clinically relevant in their dataset.
• If Apoquel is working, don’t change the drug for the sake of novelty.
• Consider Zenrelia for:
• Dogs that respond to twice‑daily Apoquel but relapse on once‑daily.
• Cases where once‑daily dosing from the start will improve owner adherence.
• Check local pricing — in many places it’s broadly comparable to Apoquel.
• Discuss and document a blood‑monitoring plan up front because of the reported haematology shifts. Practices vary: some aim for six‑monthly bloods where feasible, others use a risk‑stratified approach (older dogs or those with comorbidities monitored more often; otherwise annual minimum). If you can’t commit to specific timelines for a client, at least document the agreed plan and signs to watch for.
• Don’t let twice‑daily dosing become “forever” without a review date. If you inherit a dog on permanent twice‑daily dosing, reset expectations and document the plan.
• Cytopoint remains a very useful, different tool (injectable; owners often like the hands‑off option). For cats, systemic options are limited and need careful consent about immunosuppression risks.

4.Librela — cautious, not panicked

What’s changed

How we’re approaching it in GP

What to tell owners

Short owner script

“Librela often helps older arthritic dogs. There have been rare reports of fast joint deterioration in some younger referral cases, so here’s what I’d suggest for your dog and how we’ll keep an eye on them.”

• Reports from orthopaedic referral centres described cases of rapidly progressive osteoarthritis (RPOA) in some dogs on Librela. These cases prompted reappraisal of who we start it in.
• Many older dogs with established OA do very well on Librela and owners report big improvements in comfort and quality of life.
• For young or middle‑aged dogs with orthopaedic disease (the kinds of cases typically seen at referral centres) we’re more cautious about using Librela as the sole analgesic. Some clinicians prefer to use it adjunctively in those patients while multimodal management continues.
• Remember the referral population differs from typical GP caseloads; the signal exists but comparative population‑level data are still limited.
• Be honest about uncertainty: “Librela helps many older arthritic dogs, but there are case reports suggesting rare, serious joint changes in some cohorts.”
• Keep the plan multimodal: weight, physio/exercise modulation, environment adjustment and rescue analgesia where needed.
• Agree and document a monitoring plan and a shared decision.

5.Daxo Cox (weekly NSAID) — convenience vs “what if?”

What it is

Real‑world concerns (practical, not theoretical)

Clinical pearls

• Marketed as a once‑weekly NSAID with claimed COX‑2 selectivity and a long tail of action.
• Irreversibility during the dosing window: if a dog develops vomiting/haemorrhagic diarrhoea, needs emergency corticosteroids, or becomes hypotensive under anaesthesia, you can’t “take the drug back” for the week. That worries out‑of‑hours and ECC teams.
• Compliance paradox: some clients find weekly routines easier; others forget weekly tasks more than daily ones.
• Peri‑anaesthetic decisions become trickier. Many vets prefer to give NSAIDs at the end of surgery once blood pressure is stable; a weekly drug given pre‑op removes that option. Document your peri‑op policy and rationale.
• If you’re worried about intra‑operative hypotension, defer the NSAID until the end of surgery or until recovery; document timing and reasoning.
• Always agree a “what if” plan with owners before starting any long‑tail analgesic: who to call, when to stop other meds, and emergency instructions.

6.Skin, ears and nurse‑led workflows — the unglamorous wins

High‑value, low‑tech moves

Practice move

• Cytology is gold. Aim for baseline (Day 1) and a recheck at 7–10 days where possible. If you only can do one, at least get a baseline and a planned recheck date.
• Train and empower nurses: nurse‑prepared slides and saved images that the vet reviews during the consult can make cytology routine and quicker.
• If formal bloods aren’t feasible for NSAID monitoring, a focused questionnaire and exam (water intake, nocturia, appetite, weight, demeanour) plus detailed notes is useful and defensible.
• Pilot a “cytology quick‑start”: nurse takes ear/skin samples while the owner waits so results or images are ready in the consult.

7.GI Quest — point‑of‑care faecal calprotectin

What it does

Where it might help

Caveats

• Lateral‑flow test for faecal calprotectin in dogs and cats. Calprotectin is released by activated neutrophils; higher faecal levels suggest mucosal gut inflammation.
• Cats with weight loss but relatively normal stools.
• Dogs where you’re undecided between a diet trial versus immediate further investigation/referral.
• As an objective trend marker during a strict diet trial to improve owner buy‑in.
• It’s another tool, not a silver bullet. Interpret in context (history, exam, B12/folate, imaging). Build a local protocol and price model before rolling it out.

8.“Diagnose enough to decide” — a practical ethics pathway

Scenario: suspected closed pyometra with limited funds

• Prioritise the minimal essential checks: TPR, PCV/TS if possible; focused ultrasound/AFAST to confirm effusion.
• Offer a concise consent conversation with clear options: stabilise and refer, operate here, euthanasia. Nominate one clinician to lead the conversation and document decisions and any payment plan.
• A brief, focused scan can prevent costly, unnecessary procedures — consider subsidising or absorbing it if clinically appropriate.

9.Morale and small kindnesses

• Celebrate the wins: successful stabilisations, transfusions that work and patients going home are huge for team morale.
• Small comforts for owners matter: a same‑sized, similar‑colour teddy for a bereaved guinea pig or rabbit can genuinely help during euthanasia and grief.

10.Take‑home points

Final thought

New tools are useful but don’t replace judgement: be transparent about uncertainty, pick plans both you and the owner can realistically follow, and build the checks — and the documentation — into the plan before you press “start.”

• Zenrelia is a sensible once‑daily alternative for selected dogs where Apoquel control is inadequate or once‑daily dosing matters — discuss monitoring and document the plan.
• Librela still benefits many older dogs with OA; be cautious and use shared decision‑making in younger/middle‑aged orthopaedic patients given referral‑centre reports of RPOA.
• A once‑weekly NSAID (Daxo Cox), marketed as COX‑2 selective, offers convenience but raises real practical “what if” problems (steroids, GI events, anaesthesia). Think ahead and record peri‑operative and emergency plans.
• Ear cytology and clear allergy conversations are everyday wins — nurse‑assisted workflows make them achievable.
• In‑clinic faecal calprotectin (GI Quest) may help tricky gut cases and support diet trials — make a local guideline before routine use.
• Have a simple practice playbook for “diagnose enough to decide” when finances limit options; name a decision lead and document everything.